Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 11, 2017 16:30 ET | Source: Esperion Therapeutics, Inc.

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., Aug. 11, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
August 09, 2017 21:20 ET | Source: Esperion Therapeutics, Inc.

Esperion Prices Public Offering of Common Stock

ANN ARBOR, Mich., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
August 08, 2017 16:31 ET | Source: Esperion Therapeutics, Inc.

Esperion Announces Proposed Public Offering of Common Stock

ANN ARBOR, Mich., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
August 08, 2017 08:00 ET | Source: Esperion Therapeutics, Inc.

Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2017 Financial Results

– Phase 3 Enrollment Progress Supports NDA Submissions for LDL-C Lowering Indications for Bempedoic Acid / Ezetimibe Combination Pill and Bempedoic Acid by the First Quarter 2019 –– Conference Call...
August 08, 2017 07:30 ET | Source: Esperion Therapeutics, Inc.

Esperion Announces Positive Top-Line Results From Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin

– 1002-038 Study Meets Primary Endpoint With a Robust 64% LDL-C Lowering Efficacy –– Clinically Relevant 48% hsCRP Reduction –– The Combination Therapy Was Observed to be Safe and Well-Tolerated ––...
August 02, 2017 16:30 ET | Source: Esperion Therapeutics, Inc.

Esperion to Provide Bempedoic Acid Franchise Development Program Updates and Second Quarter Financial Results

– Conference Call and Webcast on Tuesday, August 8, 2017 at 8:30 a.m. Eastern Time – ANN ARBOR, Mich., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid...
July 26, 2017 16:30 ET | Source: Esperion Therapeutics, Inc.

Esperion Announces Initiation of Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor

ANN ARBOR, Mich., July 26, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
June 26, 2017 16:05 ET | Source: Esperion Therapeutics, Inc.

Esperion Announces FDA Confirmation of Regulatory Pathway to Approval for the Combination of Bempedoic Acid and Ezetimibe

– Complementary, Non-statin, Oral Bempedoic Acid / Ezetimibe Combination Therapy Demonstrates 48% Lowering of LDL-C and Significant hsCRP Reduction with Potential for Lower Occurrence of...
June 14, 2017 16:30 ET | Source: Esperion Therapeutics, Inc.

Esperion to Present at the JMP Securities 2017 Life Sciences Conference

Presentation and Webcast on Wednesday, June 21, 2017 at 10:00 a.m. Eastern Time ANN ARBOR, Mich., June 14, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management...
May 31, 2017 16:30 ET | Source: Esperion Therapeutics, Inc.

Esperion to Present at the Jefferies 2017 Global Healthcare Conference

Presentation on Wednesday, June 7, 2017 at 10:30 a.m. Eastern Time ANN ARBOR, Mich., May 31, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused...